This weight-loss solution is now India’s second-highest selling drug

byadmin

**This Weight-Loss Solution is Now India’s Second-Highest Selling Drug**

*By Dwaipayan Roy | Oct 08, 2025, 05:14 PM*

—

**What’s the story?**

Eli Lilly’s anti-obesity and diabetes drug, Mounjaro, has taken the Indian pharmaceutical market by storm. Within just six months of its launch, the drug has become the second-best selling in India, reflecting a surge in demand for weight-loss therapies across the country.

According to Indian Pharmaceutical Market (IPM) data, Mounjaro recorded sales of ₹80 crore in September and generated total revenue of ₹233 crore since its launch.

—

**Market performance: Mounjaro’s sales soar amid growing demand**

Mounjaro’s sales witnessed an impressive 43% growth from August to September. The drug is now giving tough competition to GSK’s Augmentin, which currently leads the IPM with retail monthly sales of ₹85 crore.

Analysts attribute Mounjaro’s success primarily to its user-friendly pen formulation. Additionally, the recent Goods and Services Tax (GST) cuts are expected to further boost its sales in the coming months.

—

**Product details: Effective weight-loss drug with up to 22% efficacy**

Mounjaro offers a weight-loss efficacy of 20-22% and was launched in India in late March 2025. The drug’s sales received a significant boost following the launch of its injectable Kwikpens in August.

These disposable pens are pre-filled with the drug and are priced between ₹14,000 to ₹27,500, depending on the dosage.

—

**Sales forecast: GST cuts to further enhance sales momentum**

The reduction in GST from 18% to 5%, effective from September 22, has significantly reduced the financial burden on chronic care patients. This tax relief is expected to further accelerate Mounjaro’s sales growth in the coming months.

As the monthly cost of treatment becomes more affordable, Mounjaro is well-positioned to maintain its rapid market expansion and continued popularity among weight-loss therapies in India.
https://www.newsbytesapp.com/news/business/eli-lilly-s-mounjaro-becomes-2nd-best-selling-drug-in-india/story

Related Posts

Edelteq launches Halovision JV, secures strategic investment from Kumpulan Modal Perdana

KMP to invest up to US$672,000 in Halovision The investment will advance the Raptor and i-Falke series & provide working capital support Edelteq Holdings Berhad has announced the establishment of Halovision System Sdn. Bhd., a joint venture with Halo Technologies Sdn. Bhd., to develop and commercialise advanced Automated Optical Inspection (AOI) systems for the global semiconductor industry. As part of this milestone, Kumpulan Modal Perdana Sdn. Bhd. (KMP)a tech-focused venture capital firm wholly owned by the Minister of Finance and operating under the purview of the Ministry of Science, Technology and Innovation will invest up to US$672,000 (RM3. 2 million) in Halovision. The funds will accelerate the development of the Raptor series for substrate panel inspection and the i-Falke series for wafer-level inspection, as well as supporting working capital requirements. This partnership is a strong vote of confidence in Halovisions technology and vision. With KMPs strategic backing, we aim to accelerate product development and position Malaysia as a key contributor to the next wave of semiconductor innovation, said Chin Yong Keong, Group CEO of Edelteq Holdings Berhad. Lee Hui-Ni, Chief Investment Officer of KMP, added: We are proud to support Halovision in its journey here in Malaysia as it advances towards delivering world-class semiconductor inspection solutions. This investment underscores our deep commitment to nurturing home-grown innovation and strengthening Malaysias position in the global electronics and semiconductor value chain. Meanwhile, John Moon, CEO of Halovision System Sdn. Bhd., said: At Halovision, our mission is to push the boundaries of inspection technology to meet the evolving demands of the semiconductor industry. With the combined strengths of Edelteq, HTSB and KMP, we are confident of bringing cutting-edge solutions such as the Raptor and i-Falke series to market and establishing Halovision as a trusted technology partner globally. The creation of Halovision, together with KMPs investment, underlines Edelteqs commitment to advancing semiconductor equipment capabilities and deepening Malaysias footprint in the global high-tech ecosystem. Beyond capital deployment, the investment represents a strategic collaboration between a government-owned venture capital fund and a publicly listed company to support a pioneering Malaysian semiconductor start-up. The partnership is positioned to accelerate industry advancement in line with Malaysias National Semiconductor Strategy by cultivating local talent and technological capability, upgrading the value chain, and strengthening Malaysias role as a pivotal enabler in the global semiconductor ecosystem.

OpenAI valuation soars to $500B in private share sale – reports

PARIS, France — The valuation of ChatGPT developer OpenAI soared to a chart-topping $500 billion in a deal for employees to sell a limited number of shares, financial media reported Thursday. If confirmed, OpenAI workers’ sale of a reported $6.6 billion in shares to investors would make the company the world’s most valuable startup, overtaking Elon

Leave a Reply

Your email address will not be published. Required fields are marked *